rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Rigel Pharmaceuticals, Inc.

RIGL · Nasdaq

Health CarePharmaceuticalsIn trend

RIGL stood above a rising 150-day average in 23 of the last 52 weekly readings, including each of the last 8 weeks. It is 25.3% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
8 in a row
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$612K
Officials’ trades on record
0
Institutions holding
149 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$409K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 2
WhoDidSharesTraded
Kamil Ali-JacksonDirectorsold2,500at $35.0022 Jun 2026filed 24 Jun 2026
Kamil Ali-JacksonDirectorsold2,500at $29.1726 May 2026filed 28 May 2026
Walter H. MoosDirectorsold4,000at $36.3620 Feb 2026filed 24 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders149+6 on the quarter
New · exited37 · 26
Reported value$591.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,943,334$75.9M+170,911+9.6%
Soleus Capital Management, L.P.added · filed 11 Aug 20261,843,504$72.1M+1,833,504+18335.0%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20261,672,000$65.4M+392,000+30.6%
STATE STREET CORPreduced · filed 7 Aug 20261,039,994$40.7M-80,244−7.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026802,082$30.7M+20,914+2.7%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026741,718$29.0M+197,287+36.2%
D. E. Shaw & Co., Inc.added · filed 14 Aug 2026542,539$21.2M+96,861+21.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026501,576$18.9M+21,477+4.5%
MARSHALL WACE, LLPreduced · filed 13 Aug 2026367,393$14.4M-230,985−38.6%
CM Management, LLCadded · filed 13 Aug 2026250,000$9.8M+15,000+6.4%
30 Jun 2024 – 30 Jun 2026
76122168Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Dean L. Schorno Company insiderEVP & Chief Financial Officer · last 2 Sep 20261 · 5
David A. Santos Company insiderEVP, Chief Commercial Officer · last 1 Sep 20260 · 5
Raul R. Rodriguez Company insiderCEO, President · last 1 Sep 20262 · 5
Raymond J. Furey Company insiderEVP, GC, CCO & Corp Sec · last 1 Sep 20260 · 2
Alison L. Hannah Company insiderEVP, Chief Medical Officer · last 8 Jul 20260 · 0
Kamil Ali-Jackson Company insiderDirector · last 22 Jun 20260 · 2
Lisa Rojkjaer Company insiderEVP, Chief Medical Officer · last 17 Jun 20260 · 0
Anthony Gregg Lapointe Company insiderDirector · last 15 May 20260 · 0
Jane Wasman Company insiderDirector · last 15 May 20260 · 0
Mark W. Frohlich Company insiderDirector · last 15 May 20260 · 0
Michael Patrick Miller Company insiderDirector · last 15 May 20260 · 0
Walter H. Moos Company insiderDirector · last 15 May 20260 · 1

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202593.3%
Operating profit marginFY 2025 · to 31 Dec 202542.6%
Return on capital employedFY 2025 · to 31 Dec 202530.3%
Cash conversionFY 2025 · to 31 Dec 202520.6%
Debt to equityFY 2025 · to 31 Dec 20250.13×
Research spendFY 2025 · to 31 Dec 202511.3%
Share count trendFY 2025 · to 25 Feb 20260.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$40.6M

Analyst forecasts

No analyst forecasts yet.